These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23550899)

  • 21. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
    Bridgeman MB; Friia NJ; Taft C; Shah M
    Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
    Andersson KE; Martin N; Nitti V
    J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
    Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE
    BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mirabegron for overactive bladder syndrome.
    Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
    Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
    Caremel R; Loutochin O; Corcos J
    Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
    Nitti VW; Chapple CR; Walters C; Blauwet MB; Herschorn S; Milsom I; Auerbach S; Radziszewski P
    Int J Clin Pract; 2014 Aug; 68(8):972-85. PubMed ID: 24703195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
    Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
    J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirabegron: A new option in treating overactive bladder.
    Turpen HC; Zimmern PE
    JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
    Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
    J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
    Sharaf A; Hashim H
    Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
    Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
    Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
    Chapple C; Khullar V; Nitti VW; Frankel J; Herschorn S; Kaper M; Blauwet MB; Siddiqui E
    Eur Urol; 2015 Jan; 67(1):11-14. PubMed ID: 25092537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.